Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01111890
Recruitment Status : Completed
First Posted : April 28, 2010
Last Update Posted : July 29, 2015
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
Subjects are dosed twice daily at 9AM and 9PM for 12 weeks. The primary efficacy variable is the mean change in Intraocular Pressure (IOP) from baseline to 12 weeks. Secondary efficacy variable: % IOP ≤ 18 millimeters mercury (mmHg). Exploratory endpoint: Ocular discomfort scale after first dose.

Condition or disease Intervention/treatment Phase
Glaucoma Ocular Hypertension Drug: Azarga (brinzolamide 1% / timolol 0.5%) Drug: Cosopt (dorzolamide 2% / timolol 0.5%) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Study Start Date : April 2010
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: Azarga
Azarga (brinzolamide 1% / timolol 0.5%)
Drug: Azarga (brinzolamide 1% / timolol 0.5%)
Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks

Active Comparator: Cosopt
Cosopt (dorzolamide 2% / timolol 0.5%)
Drug: Cosopt (dorzolamide 2% / timolol 0.5%)
Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks

Primary Outcome Measures :
  1. Mean change in Intraocular Pressure (IOP) following 12 weeks of twice daily dosing [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Percentage of subjects with IOP ≤ 18 millimeters mercury (mmHg) [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must be at least 18 years of age.
  2. Must have a clinical diagnosis of ocular hypertension, primary open-angle or pigment dispersion glaucoma in at least one eye (study eye).
  3. Must have IOP considered to be safe, in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period.
  4. Must be willing to discontinue the use of all other ocular hypotensive agents prior to receiving the assigned study drug at Visit 1, throughout the study period.
  5. Must have an IOP of between 19 to 35 mmHg in at least one eye (which would be the study eye).
  6. For the eyes not included in the study, the intraocular pressure should be able to be controlled on no pharmacologic therapy or on the study medicine alone.

Exclusion Criteria:

  1. Known medical history of allergy, hypersensitivity or poor tolerance to any components of the preparations to be used in this study that is deemed clinically significant in the opinion of the Principal Investigator.
  2. Presence of other primary or secondary glaucoma not listed in inclusion criterion #2.
  3. Any abnormality preventing reliable applanation tonometry in study eye(s).
  4. Risk of visual field or visual acuity worsening due to participation in the study, in the investigator's best judgment.
  5. Progressive retinal or optic nerve disease from any cause.
  6. Use of systemic medications known to affect IOP (e.g., oral beta-adrenergic blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for 7 days prior to Day 1 Visit or an anticipated change in the dosage during the course of the study.
  7. A condition, which in the opinion of the Principal Investigator, would interfere with optimal participation in the study, or which would present a special risk to the subject.
  8. Participation in any other investigational study within 30 days prior to Visit 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01111890

Layout table for location information
Canada, Ontario
Mississauga, Ontario, Canada, L5L 1W8
Sponsors and Collaborators
Alcon Research

Layout table for additonal information
Responsible Party: Alcon Research Identifier: NCT01111890    
Other Study ID Numbers: SMA-09-17
First Posted: April 28, 2010    Key Record Dates
Last Update Posted: July 29, 2015
Last Verified: January 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors